Novel, Highly Specific Therapeutic Target for Neuroendocrine Prostate Cancer Identified by VPC Scientists

Date Posted: 
2015-07-30

Drs. Akamatsu, Wyatt, Gleave and Collins and their team at the VPC have published the result of their ground-breaking work identifying a gene called PEG10 as a novel and highly-specific therapeutic target for neuroendocrine prostate cancer (NEPC) ("The placental gene PEG10 promotes progression of neuroendocrine prostate cancer", Cell Reports, published online).

NEPC is the most common form of prostate cancer that does not rely on the androgen receptor. There are few treatments for NEPC, and due to its fast growth rate and ability to metastasize, patient life expectancy after NEPC diagnosis is short. NEPC can evolve from typical prostate cancer by an adaptive response of the cancer cells while under the stress of treatment.

The team studied this adaptive response and identified key genes that were associated with the malignant aspects of clinical NEPC. One of the genes with increased expression, PEG10, is a gene that is normally only 'switched-on' during the development of the placenta. When PEG10 is aberrantly switched-on again early during NEPC development, it increases proliferation of cancer cells and promotes metastasis. Blocking PEG10 activity in model systems resulted in reduced tumor growth and restricted invasion of the surrounding normal tissue.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Fathers Day Walk Run 2019

Raymond James Father's Day Walk Run Fundraiser, June 16, 2019

The 21st Annual Raymond James Walk Run fundraiser for Prostate Cancer Foundation BC took place on Sunday June 16, 2019 in various locations across BC. The sponsorship page is still accepting donations;  click here to sponsor our Centre's team (opens in new window).

 

Employment

Work at the Vancouver Prostate Centre

Monday, July 8, 2019

Dr. Flannigan to lead clinical trial for scrotal pain treatment

Dr. Flannigan
Monday, June 3, 2019

Benefits Seen With Apalutamide Plus ADT in Metastatic Castration-Sensitive Prostate Cancer

Dr. Chi